Lobe Sciences Ltd. Acquires Altemia & Company, LLC

Afya Limited Acquires Além da Medicina

March 4, 2022

Healthcare Services

Afya Limited executed a purchase agreement to acquire 100% of the total share capital of Além da Medicina through its wholly owned subsidiary Afya Participações S.A. The transaction was structured with an enterprise value of R$16.0 million paid to sellers in cash, with an additional earn-out of up to R$19.2 million tied to 2023 and 2024 revenue goals. Afya later announced the acquisition closed.

Ipsen Acquires Albireo Pharma

January 9, 2023

Biotechnology

Ipsen has agreed to acquire Albireo Pharma in a cash tender offer of $42.00 per share plus a contingent value right (CVR) tied to FDA approval in biliary atresia, in a transaction intended to expand Ipsen's Rare Disease portfolio. The acquisition brings Albireo's approved pediatric liver drug Bylvay (odevixibat) and a pipeline of bile-acid modulators into Ipsen's global R&D and commercial capabilities.

Calian Group Acquires Allphase Clinical Research and Alio Health Services

January 31, 2020

Healthcare Services

Calian Group Ltd. announced the acquisition of Ottawa-based Allphase Clinical Research Services Inc. and Alio Health Services Inc., bringing clinical trial management, patient support program capabilities and a proprietary home-care scheduling software into Calian’s Health segment. The deal consideration included $12.0 million in cash, 62,054 common shares and up to $12.0 million of earnouts tied to future EBITDA, with Calian planning to integrate the HOMETM application across its health services to drive new business and efficiencies.

Aileron Therapeutics Acquires Lung Therapeutics

October 31, 2023

Biotechnology

Aileron Therapeutics, Inc. (NASDAQ: ALRN) completed a stock-for-stock acquisition of Lung Therapeutics, Inc., bringing the clinical-stage pulmonary and fibrosis-focused pipeline (including lead candidate LTI-03) into Aileron's portfolio. Immediately after the acquisition Aileron arranged a private placement led by Bios Partners (with participation from Nantahala Capital and others) to raise approximately $18 million to fund ongoing development, including a Phase 1b trial of LTI-03.

Astorg to Acquire Majority Stake in Solabia Group

May 7, 2025

Biotechnology

Astorg has signed a definitive agreement to acquire a majority stake in Solabia Group from TA Associates, with TA reinvesting alongside Astorg. Solabia, a Paris-headquartered biotech ingredients manufacturer with 11 production sites, 8 R&D labs and over 900 employees, will partner with Astorg to accelerate international expansion (particularly in the US and Asia), advance product innovation and pursue targeted M&A.

VitalHub Corp. Acquires Alamac Limited

July 5, 2021

Healthcare Services

VitalHub Corp. (TSXV: VHI) acquired UK-based Alamac Limited via its wholly-owned subsidiary The Oakgroup (UK) Limited for a cash purchase price of £1,850,000. The acquisition adds Alamac's patient-flow business intelligence platform and recurring contracted revenue to VitalHub's healthcare software portfolio, expanding its patient flow and operational visibility capabilities for NHS customers.